Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern
批准号:
10706895
负责人:
MARTIN G SANDA
金额:
$72.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
未结题
起止时间:
2005-03-29 至 2028-06-30
关键词:
AddressAdherenceAfrican AmericanAfrican American populationAlabamaAlgorithmsAmericanArtificial IntelligenceBiological AssayBiological MarkersBiomedical EngineeringBiopsyBlindedBlood TestsCancer Intervention and Surveillance Modeling NetworkClinicalClinical DataClinical TreatmentCollaborationsCountryDataDetectionDiagnosisDiagnosticDiseaseEarly Detection Research NetworkEnrollmentEnzyme-Linked Immunosorbent AssayFOLH1 geneFacultyFosteringFundingGenesGenetic TranscriptionGoalsHealthHospitalsImageImaging TechniquesImpact evaluationIndolentIndustryInvestigationKLK3 geneLaboratoriesLeadershipMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMedical centerMichiganNested Case-Control StudyNomogramsOncologyPET/CT scanPatientsPerformancePhasePositron-Emission TomographyProgress ReportsProstatePublicationsPublishingRNAResearch DesignResearch PersonnelResourcesScreening for Prostate CancerSerumSpecimenTMPRSS2 geneTechniquesTestingTexasTissuesTranslatingUnited States National Institutes of HealthUniversitiesUniversity HospitalsUrineValidationWorkadvanced prostate cancerbiomarker discoverycancer biomarkerscancer carecancer imagingcareer developmentcase controlclinical research siteclinically significantcohortcost effectivenesscost-effectiveness evaluationdeep learningdesigndetection methoddigital healthhealth care settingsimprovedindexinginnovationmenovertreatmentphase IV trialpredictive modelingprospectiveprostate biopsyprostate cancer riskradiotracertranscriptomeurinaryvalidation studies
中文摘要
我们假设,新的生物标志物,以完善选择男性前列腺活检,连同成像,
改进活检靶向的创新,将通过减少不必要的
活组织检查和惰性疾病的过度检测。为了实现这一目标,我们通过以下方式收集了生物标本和成像数据:
活检前队列中严格的SOP旨在避免偏倚。我们提供了标本和指导PRoBE
遵守EDRN实验室、NIH联盟(如SPORE)和行业,并在之前的周期中共同领导EDRN研究
这促进了FDA批准前列腺健康指数(phi)和尿PCA 3。在当前周期中,我们
入组了3,263例受试者,并向25名PI分发了27,072份生物标本,导致56篇出版物。我们的多-
结合尿PCA 3和TMPRSS 2:Erg(T2:Erg)测量的算法的中心III期验证
验证了这种生物标志物组合的成本效益。然后我们展示了
依次检测血液phi,然后进行条件尿PCA 3和T2:Erg检测。此外,我们还与
与具有将组织RNA测定引入监管批准的专业知识的商业合作者,
临床使用,完成多中心病例对照的全转录组尿RNA表达分析
587名男性的队列,解决了33个基因的预测模型,显着提高了侵略性的预测
前列腺癌与PSA、临床因素或尿PCA 3和T2:Erg相比。来促进前列腺癌的发展
成像,我们完成了第二阶段的验证研究,使用放射性示踪剂氟氯昔洛韦(FACBC)在PET-CT,
在初步诊断时表征前列腺癌的侵袭性(据我们所知,这是第一次完成
FACBC PET-CT用于原发性、未经治疗的早期前列腺癌的美国验证研究)。为此
更新,我们通过增加UAB和UTSW(其中,与埃默里,招收了大多数学生)来扩大我们的包容性。
EDRN前列腺MRI试验中的非洲裔美国人)。对于这次重新提交,两个生物医学工程,
人工智能(AI)方面的调查专家加入了我们的CVC,他们带来了初步数据,支持
经过严格开发、回顾性验证的深度学习MRI AI诺模图,可预测活检的PCa,
准备好进行前瞻性验证基于尿RNA生物标志物的综合初步数据,
AI和PET成像,我们现在提出以下目标:1)为了验证,通过
采用PROBE设计的巢式病例对照研究,33个基因的尿RNA组在预测
活检的侵袭性前列腺癌; 2)使用MRI AI验证基于深度学习的诺模图,以预测
3)评估PET-MRI在检测临床前列腺癌中的性能,
4)与CISNET一起对这些措施的影响进行成本效益评估
新的生物标志物、成像和检测技术。最后,我们承诺继续作为合作伙伴,
通过领导和参与预留和核心合作研究,为欧洲数据和记录网络提供资源,
向EDRN BCC和其他合作生物标志物实验室提供生物样本和盲态临床数据。
英文摘要
We hypothesize that new biomarkers to refine selecting men for prostate biopsy, together with imaging
innovations to refine biopsy targeting, will enhance prostate cancer early detection by reducing unnecessary
biopsy and over-detection of indolent disease. With this goal, we assembled biospecimen and imaging data via
rigorous SOP's in pre-biopsy cohorts designed to avoid bias. We provided specimens and guidance on PRoBE
adherence to EDRN Labs, NIH Consortia (eg SPOREs) and industry and co-led, in prior cycles, EDRN studies
that facilitated FDA approval of the Prostate Health Index (phi) and urinary PCA3. In the current cycle, we
enrolled 3,263 subjects and distributed 27,072 biospecimens to 25 PI's leading to 56 publications. Our multi-
center phase III validation of an algorithm combining urinary PCA3 and TMPRSS2:Erg (T2:Erg) measurement
validated the cost-effectiveness of this biomarker combination. We then showed significant benefit of
sequentially testing blood phi followed by conditional urine PCA3 and T2:Erg testing. Further, we partnered
with a commercial collaborator having expertise in bringing tissue RNA assays to regulatory approval and
clinical use, to complete whole transcriptome urinary RNA expression analysis in a multi-center case-control
cohort of 587 men, resolving a 33-gene predictive model that significantly improved prediction of aggressive
prostate cancer compared to PSA, clinical factors, or urinary PCA3 and T2:Erg. To advance prostate cancer
imaging, we completed a phase II validation study using the radiotracer fluciclovine (FACBC) in PET-CT to
characterize aggressiveness of prostate cancer at initial diagnosis (to our knowledge, this was first completed
American validation study of FACBC PET-CT for primary, untreated, early stage prostate cancer). For this
renewal, we expand our inclusiveness by adding UAB and UTSW (which, with Emory, enrolled the majority of
African-Americans in EDRN's Prostate MRI trial). For this resubmission, two biomedical engineering
investigators expert in Artificial Intelligence (AI) have joined our CVC, who bring preliminary data supporting a
rigorously developed, retrospectively validated deep-learning MRI AI nomogram to predict PCa on biopsy that
is poised for prospective validation. Based on the combined preliminary data in urinary RNA biomarkers, MRI
AI, and PET imaging from our expanded CVC team, we now propose the following Aims: 1) To validate, by
nested case-control study using PROBE design, the performance of a 33-gene urinary RNA panel in predicting
aggressive prostate cancer on biopsy; 2) To validate a deep learning-based nomogram using MRI AI to predict
aggressive prostate cancer on biopsy 3) To evaluate the performance of PET-MRI in the detection of clinically
significant prostate cancer; 4) To conduct, with CISNET, cost-effectiveness evaluation of the impact of these
new biomarker, imaging and detection techniques. Finally, we commit to continuing to serve as a Collaborative
Resource for the EDRN, through leadership and participation in Set-Aside and Core Collaborative Studies and
provision of biospecimens and blinded clinical data to EDRN BCC's and other collaborating biomarker labs.
期刊论文(74)
专著(0)
科研奖励(0)
会议论文
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
-
批准号:7830026
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MARTIN G SANDA
-
依托单位:
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
-
批准号:7937838
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:MARTIN G SANDA
-
依托单位:
University of Michigan O'Brien Center for Urology Research
-
批准号:7500609
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2007
-
负责人:MARTIN G SANDA
-
依托单位:
University of Michigan O'Brien Center for Urology Research
-
批准号:7500610
-
项目类别:
-
资助金额:$2.39万
-
财政年份:2007
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:7242542
-
项目类别:
-
资助金额:$83.66万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
-
批准号:8326753
-
项目类别:
-
资助金额:$68.97万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center
-
批准号:10375666
-
项目类别:
-
资助金额:$58.47万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
-
批准号:8738615
-
项目类别:
-
资助金额:$62.47万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:7405382
-
项目类别:
-
资助金额:$82.64万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:7632242
-
项目类别:
-
资助金额:$84.35万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
-
批准号:7982939
-
项目类别:
-
资助金额:$75.66万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
-
批准号:8510590
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center
-
批准号:9763469
-
项目类别:
-
资助金额:$78.72万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:8052049
-
项目类别:
-
资助金额:$23.36万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:7037460
-
项目类别:
-
资助金额:$84.53万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
-
批准号:6909287
-
项目类别:
-
资助金额:$68.99万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
-
批准号:8138508
-
项目类别:
-
资助金额:$69.91万
-
财政年份:2005
-
负责人:MARTIN G SANDA
-
依托单位:
Survivor QOL/Spouse Satisfaction after Prostate Therapy
-
批准号:6623053
-
项目类别:
-
资助金额:$58.03万
-
财政年份:2002
-
负责人:MARTIN G SANDA
-
依托单位:
Survivor QOL/Spouse Satisfaction after Prostate Therapy
-
批准号:6953079
-
项目类别:
-
资助金额:$62.32万
-
财政年份:2002
-
负责人:MARTIN G SANDA
-
依托单位:
Survivor QOL/Spouse Satisfaction after Prostate Therapy
-
批准号:7495251
-
项目类别:
-
资助金额:$22.26万
-
财政年份:2002
-
负责人:MARTIN G SANDA
-
依托单位:
海外基金